期刊
THERAPEUTIC INNOVATION & REGULATORY SCIENCE
卷 56, 期 6, 页码 991-1003出版社
SPRINGER HEIDELBERG
DOI: 10.1007/s43441-022-00410-3
关键词
Child; Adolescent; Drug development; Stakeholders; Engagement; Health equity; Access
资金
- National Cancer Institute [P30 CA21765]
- American Lebanese Syrian Associated Charities (ALSAC)
- ViiV Healthcare
The concept of health equity requires equitable access to healthcare, including pediatric drug development. However, many communities are under-represented in pediatric drug development programs. Community engagement and collaboration are recognized as crucial for building a more equitable healthcare system.
The concept of health equity-the attainment of the highest possible level of health for all members of society-requires equitable access to all aspects of healthcare, including pediatric drug development. However, many communities are under-represented in pediatric drug development programs. Barriers to participation include geographic, economic, racial/ethnic bias, legal, cultural, linguistic, and other factors. While there is no one size fits all approach to addressing these barriers, community engagement and collaboration is recognized by the Centers for Disease Control, the World Health Organization, and other global health organizations as a cornerstone for building a more equitable healthcare system. In this article, we will present case studies of stakeholder and community engagement in clinical research for rare diseases and other areas of healthcare, as examples of strategies and practices for actively involving under-represented communities and fostering their participation in pediatric drug development programs. These studies may serve as templates for facilitating equity in pediatric drug development from aspiration into operation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据